This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tremblay, C. L.
Right arrow Articles by Hirsch, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tremblay, C. L.
Right arrow Articles by Hirsch, M. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2005, p. 3483-3485, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3483-3485.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

TAK-220, a Novel Small-Molecule CCR5 Antagonist, Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro

Cécile L. Tremblay,1,4 Françoise Giguel,1 Yongbiao Guan,2 Ting-Chao Chou,2 Katsunori Takashima,3 and Martin S. Hirsch1*

Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Cambridge, Massachusetts,1 Memorial Sloan-Kettering Cancer Center, New York, New York,2 Takeda Pharmaceutical Company, Ltd., Osaka, Japan,3 Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada4

Received 22 December 2004/ Returned for modification 8 March 2005/ Accepted 25 April 2005

TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various antiretrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted.

* Corresponding author. Mailing address: Massachusetts General Hospital, 65 Landsdowne St., Room 419, Cambridge, MA 02139. Phone: (617) 768-8370. Fax: (617) 768-8738. E-mail: mshirsch{at}partners.org.

Antimicrobial Agents and Chemotherapy, August 2005, p. 3483-3485, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3483-3485.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Nakata, H., Steinberg, S. M., Koh, Y., Maeda, K., Takaoka, Y., Tamamura, H., Fujii, N., Mitsuya, H. (2008). Potent Synergistic Anti-Human Immunodeficiency Virus (HIV) Effects Using Combinations of the CCR5 Inhibitor Aplaviroc with Other Anti-HIV Drugs. Antimicrob. Agents Chemother. 52: 2111-2119 [Abstract] [Full Text]  
  • Murga, J. D., Franti, M., Pevear, D. C., Maddon, P. J., Olson, W. C. (2006). Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1.. Antimicrob. Agents Chemother. 50: 3289-3296 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»